title: [Proliferation and apoptosis of choriocarcinoma cell JEG-3 induced by VB2 and its in vitro mechanism].
abstract: OBJECTIVE
  To investigate the effect of purified vitexin compound 2 (VB2), a noval lignanoid from the acetoacetate extract of Vitex negundo seed on the proliferation and apoptosis as well as the expression of mTOR and 4E-BP1 mRNA signal pathway in human choriocarcinoma JEG-3 cell lines in vitro.
  
  
  METHODS
  The inhibitory effect of different concentrations of VB2 on JEG-3 cells was examined by methyl thiazolyl tetrazolium (MTT) assay. Flow cytormetry was used to analyze the apoptosis after using different concentrations of VB2, and the expression of mTOR and 4E-BP1 mRNA was determined by RT-PCR.
  
  
  RESULTS
  The inhibitory rate of JEG-3 cell growth which was cultured with different concentrations of VB2 (2.5, 5.0, 10.0, 20.0, 40.0, 80.0, and 160.0 μmol/L) for 24, 48, or 72 hours increased from (6.34±0.41)% to (85.89±0.81)%, and it was positively correlated with the dose and time of culture (P<0.05). VB2 at 5.0, 10.0, or 20.0 μmol/L increased the rate of JEG-3 cell apoptosis in vitro from (9.26±1.02)% to (35.55±1.24)% after 48 hour culture, which was in a dose dependent manner (P<0.05), while 5.0, 10.0, or 20.0 μmol/L of VB2 down-regulated the mRNA levels of mTOR and 4E-BP1 after 48 hour culture, which presented a significant negative correlation between VB2 and the mRNA levels of mTOR and 4E-BP1(P<0.05).
  
  
  CONCLUSIONS
  VB2 can restrain the proliferation of choriocarcinoma cell JEG-3 and induce its apoptosis. This effect may be related to the inhibition of VB2 on the mRNA expression of JEG-3 cell mTOR and 4E-BP1.
authors.affiliation: (Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Deng
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Zhihui
authors.initials: Z
authors.lastname: Tan
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D047310:Apigenin / Q000302:isolation & purification / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D018797:Cell Cycle Proteins; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002822:Choriocarcinoma / Q000473:pathology*; D005260:Female; D006801:Humans; D010750:Phosphoproteins / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D014594:Uterine Neoplasms / Q000473:pathology; D020950:Vitex / Q000737:chemistry*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000972:Antineoplastic Agents, Phytogenic; D018797:Cell Cycle Proteins; C087000:EIF4EBP1 protein, human; D010750:Phosphoproteins; D047310:Apigenin; C032731:vitexin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases